Skip to NavigationSkip to content

Purdue Pharma

Purdue Pharma vow not to profit from fast tracked opioid overdose antidote

The FDA has granted OxyContin drugmaker Purdue Pharma, fast track designation for opioid overdose antidote nalmefene hydrochloride (HCl) injection. However, the besieged firm has vowed not to profit from sales of the drug.

The pledge comes after evidence presented in court showed Purdue executives had discussed their hopes of entering the lucrative and ‘attractive’ market for addiction treatments as early as 2014.

OxyContin drugmaker Purdue Pharma exploring bankruptcy, sources say

OxyContin drugmaker Purdue Pharma is exploring the option of filing for bankruptcy. The news comes as the Connecticut-based firm faces thousands of lawsuits over allegations the company’s actions contributed to the opioid crisis in the United States.

Speaking to news agency Reuters, people familiar with the matter have said that Purdue are exploring bankruptcy as a means of deflecting more than 1,000 lawsuits related to the company’s role in the opioid epidemic.

Eisai and Purdue reveal positive Phase 3 data in insomnia

Partners Eisai and Purdue Pharma have lifted the curtain on Phase 3 clinical data on their jointly developed therapy lemborexant in the treatment of insomnia.

The data, derived from 949 adults (28% of which were over 50), revealed that, after six months receiving either 5 or 10mg, patients experienced “significant improvements” in patient-reported sleep onset latency (sSOL), meeting the trial’s primary endpoint. Specifically, the 5mg group saw median improvements of 21.81 minutes and the 10mg saw a median reduction of 28.21 minutes, compared to 11.43 with placebo.

Purdue Pharma sought to expand into opioid addiction treatments while using McKinsey to counter "emotional messages"

OxyContin drugmaker Purdue Pharma explored expanding into the market for opioid addiction treatments, according to passages from court documents that had previously been withheld.

Beginning in 2014, Purdue Pharma executives discussed the ways in which the sales of opioids and treatments for opioid addiction are “naturally linked” as they suggested that the company should expand across “the pain and addiction spectrum”.

Opioid drugmaker Purdue Pharma inks deal with Alivio over non-opioid inflammation drug

Opioid drugmaker Purdue Pharma has entered into an agreement with inflammatory disease specialist Alivio Therapeutics for the development of the non-opioid treatment for interstitial cystitis/bladder pain syndrome, ALV-107.

Alivio will receive $14.75 million upfront and will be eligible to receive more than $260 million in royalties if developmental milestones are met.

Sacklers accused of personally directing deceptive OxyContin sales tactics

Members of the billionaire Sackler dynasty personally directed efforts to mislead doctors and patients as to the dangers of the powerful opioid painkiller OxyContin, thus creating the opioid crisis, according to a complaint filed by Massachusetts Attorney General, Maura Healey.

Purdue-owning Sackler family own second opioid drug maker, FT reveals

Image Credit: User:OgreBot/Watercraft/2016 October 11

The billionaire Sackler family, the owners of OxyContin drugmaker Purdue Pharma, have been revealed to own a second opioid drug producing company, according to the Financial Times.

Top Ten most popular articles on this week

This week’s pharmaceutical headlines were dominated by legal spats as the state of New York sued OxyContin drug maker Purdue Pharma and a Chicago judge overturned a $140 million verdict against AbbVie while Indian biotech owner Nitin Sandesara was detained in Dubai.

Purdue culls 350 positions, eradicates sales force

Bowing to the pressure applied by external groups for the part it has played in the ongoing opioid crisis, Purdue Pharma has announced that it has axed around 350 employees from the company, a move which also includes the eradication of the remainder of its already-gutted sales force.

Purdue pulls plug on opioid marketing

Purdue Pharma was fined $643.5 million in 2007 for its part in creating the opioid epidemic that has plagued the US for the last decade. The punishment was meted out on the back of a marketing campaign that denied that its Oxycontin product was dangerously addictive.

Fast forward over 10 years and the US is still suffering the catastrophic effects of the opioid crisis. It was calculated that in 2015 alone, the high levels of addiction to opioids cost the economy $504 billion – putting the large fine that Purdue faced firmly in the shadow.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches